Scleromate

Drug Overview

In the field of hematology and vascular medicine, managing damaged, swollen, or bleeding veins is crucial for patient safety and comfort. Scleromate is a specialized medication classified as a Sclerosing Agent. It is used to intentionally close off diseased veins, directing blood flow to healthier pathways and preventing life-threatening bleeding.

For patients dealing with the complications of chronic liver disease (which often causes severe vein issues) or painful varicose veins, this medication offers a direct, localized treatment option.

Generic Name: morrhuate sodium
US Brand Names: Scleromate
Route of Administration: Intravenous (IV) injection directly into the target vein
FDA Approval Status: FDA-regulated prescription medication originally approved for the obliteration of primary varicose veins. It is also widely used in clinical practice for the treatment of bleeding esophageal varices.

What Is It and How Does It Work? (Mechanism of Action)

When injected directly into a diseased vein, it works at the cellular and hematological level through the following steps:

Endothelial Damage: The medication immediately irritates and damages the endothelium (the delicate inner lining of the vein).
Coagulation Cascade Activation: This deliberate damage exposes the tissue underneath the lining. The body senses this as an injury and immediately activates the coagulation cascade (the body’s natural blood-clotting system).
Thrombus Formation: Platelets rush to the area, stick together, and form a localized blood clot (thrombus) that completely blocks the targeted vein.
Fibrosis and Obliteration: Over a few weeks, the body replaces this blood clot with scar tissue (fibrosis). The diseased vein is permanently sealed shut and eventually reabsorbed by the body.

In hematology, this mechanism provides vital hemorrhage risk reduction. For instance, in esophageal varices (fragile, swollen veins in the food pipe), sealing the veins prevents them from bursting and causing massive, life-threatening internal bleeding.

FDA-Approved Clinical Indications

Primary Indication

The specific use for Scleromate is the obliteration of problematic veins.

Esophageal Varices: In patients with severe liver disease, blood flow to the liver is blocked, causing blood to back up into the veins of the lower esophagus. These veins become swollen and fragile. Scleromate is injected directly into these varices during an endoscopy to seal them and stop or prevent acute internal bleeding.
Varicose Veins: It is also used to treat primary varicose veins of the legs that are painful or prone to bleeding. By sealing these swollen veins, blood is naturally rerouted through healthier, deeper veins.

Other Approved & Off-Label Uses

Treatment of bleeding internal hemorrhoids (off-label).
Management of specific vascular malformations (off-label).
Treatment of hydroceles (fluid-filled sacs around the testicles) by sealing the sac lining (historical/off-label use).

Dosage and Administration Protocols

Scleromate is administered strictly by a trained healthcare professional. The dosage depends heavily on the size and location of the vein being treated. It is not based on the patient’s weight, but rather on the volume needed to fill the specific targeted vein segment.

Indication	Standard Dose (5% Solution)	Frequency	Administration Notes
Small/Medium Varicose Veins	0.5 mL to 2 mL per injection	Once per site	Maximum of 5 mL total per treatment session.
Large Varicose Veins	1 mL to 3 mL per injection	Once per site	Given via slow intravenous injection.
Esophageal Varices	1 mL to 4 mL per varix	Repeated until varices are obliterated	Administered via an endoscope directly into or around the bleeding vein.

Important Adjustments:

Maximum Infusion Rates: The injection must be given slowly. A small test dose (0.25 to 0.5 mL) is often given first to check for severe allergic reactions.
Patient Population Limits: This medication is generally contraindicated (should not be used) in patients who are completely bedridden, as their lack of movement drastically increases the risk of unwanted blood clots.
Renal/Hepatic Insufficiency: While the drug acts locally, patients with severe liver failure being treated for esophageal varices require intense monitoring for overall bleeding and clotting imbalances.

Clinical Efficacy and Research Results

Current clinical practices and study data (2020-2026) confirm that sclerotherapy remains a highly effective intervention. For acute esophageal variceal bleeding, endoscopic injection with sclerosing agents like morrhuate sodium stops active bleeding in 80 to 90 percent of cases. While endoscopic band ligation is often the first choice today, sclerotherapy is a vital, life-saving backup when banding fails or is technically too difficult.

For varicose veins, clinical data shows that sclerotherapy successfully obliterates targeted veins in the majority of patients, leading to significant improvements in leg pain, cramping, and visible swelling. The treatment is considered a highly reliable, minimally invasive alternative to surgical vein removal.

Safety Profile and Side Effects

Black Box Warning

There is no “Black Box Warning” for Scleromate. However, it carries a severe warning regarding anaphylaxis (a life-threatening allergic reaction), which can occur within minutes of injection.

Common side effects (>10%)

Aching, burning, or cramping pain at the injection site
Hyperpigmentation (brown skin discoloration along the treated vein)
Temporary swelling or hives at the injection site
Localized inflammation of the vein (phlebitis)

Serious adverse events

VTE/Thrombosis risk: Deep vein thrombosis (DVT) or pulmonary embolism (PE) can occur if the medication travels into the deep vein system and causes unwanted clotting.
Tissue Necrosis: If the medication leaks out of the vein into the surrounding tissue (extravasation), it can cause severe tissue death and skin ulcers.
Hypersensitivity: Severe allergic reactions (anaphylaxis), which can cause difficulty breathing and a dangerous drop in blood pressure.

Management Strategies

Healthcare providers must have emergency epinephrine and resuscitation equipment immediately available in case of an allergic reaction. If the patient reports severe burning during the injection, the provider will stop immediately to prevent tissue necrosis. To manage thrombosis risks, patients are instructed to wear compression stockings and walk regularly to keep blood moving in the deep veins.

Research Areas

In the 2020s, research in the field of venous disease and hematology has focused on formulating sclerosing agents into “foams” rather than liquids. Injecting the medication as a foam allows it to displace blood more effectively within the vein, increasing contact with the vein walls and allowing for lower, safer doses. Additionally, research continues on combining sclerotherapy with minimally invasive laser or radiofrequency treatments to tackle extremely large varicose veins without surgery.

Disclaimer: The research mentioned regarding the use of marstacimab in patients with inhibitors and in pediatric populations under 12 is an active area of investigation in 2026. While the “rebalancing” concept is theoretically ideal for inhibitor patients, specific FDA approval for these groups is distinct from the current approval for non-inhibitor patients.

Patient Management and Practical Recommendations

Pre-treatment Tests

Coagulation Panel (PT/INR/aPTT): To ensure the patient’s blood is not too thin, especially critical for patients with liver disease.
Complete Blood Count (CBC): To check baseline red blood cells and platelets.
Liver Function Tests: Crucial for patients undergoing treatment for esophageal varices to assess overall liver health.
Ultrasound: A Doppler ultrasound of the legs is usually done before treating varicose veins to map the blood flow and rule out existing deep vein blood clots.

Precautions during treatment

Extravasation Vigilance: The doctor will closely monitor the injection site to ensure the medicine stays strictly inside the vein.
Allergy Observation: Patients should be observed in the clinic for at least 30 minutes after the injection to monitor for any delayed hypersensitivity reactions.

“Do’s and Don’ts” List

DO walk for 15 to 30 minutes immediately after leg vein treatment to prevent unwanted blood clots in the deep veins.
DO wear prescribed compression stockings day and night for the first few days after leg treatment, as directed by your doctor.
DO report any sudden shortness of breath, chest pain, or severe leg swelling to emergency services immediately.
DON’T take hot baths, sit in saunas, or apply hot compresses to the treated areas for at least 48 hours.
DON’T participate in heavy weightlifting or strenuous, high-impact exercise for a few days after treatment.
DON’T take aspirin or other blood-thinning pain relievers right before or after treatment unless specifically cleared by your doctor.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. Sclerotherapy involves the intentional formation of blood clots and carries risks of severe allergic reactions. Always consult your hematologist, gastroenterologist, or vascular specialist to discuss your specific medical condition and treatment options.